Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
United States
Northwestern University ( Site 0101), Chicago, Illinois Israel
Rambam Health Care Campus ( Site 0201), Haifa Sheba Medical Center ( Site 0200), Ramat Gan Netherlands
Radboudumc ( Site 0301), Nijmegen, Gelderland Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0300), Amsterdam, North Holland